Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C > T polymorphism

Pharmacogenomics Journal

Volumn 7, Issue 5, 2007, Pages 305-311

  Tiwari, A K ^a   Deshpande, S N ^b   Lerer, B ^c   Nimgaonkar, V L ^d   Thelma, B K ^a  

^a UNIVERSITY OF DELHI   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CONTROLLED STUDY; EXON; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP1A2; DNA MUTATIONAL ANALYSIS; DYSKINESIA, DRUG-INDUCED; EXONS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTRONS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34748868401     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500415     Document Type: Article

References (28)

1. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981; 138: 1618-1619.
2. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379.
3. Kane JM, Smith JM. Tardive Dyskinesia: Prevalence and risk factors 1959 to 1979. Arch Gen Pscychiaty 1982; 39: 473-481.
4. Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992; 32: 580-594.
5. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000; 61: 525-541.
6. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17: 47-62.
7. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65(Suppl 9): 25-28.
8. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: The quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-2530.
9. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-118.
10. Shimada T, Yamazaki H, Mimura M, Inui Y, Gungerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Ther 1994; 270: 414-423.
11. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA et al. A functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene: Association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410-417.
12. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamakati T. Genetic polymorphism in the 5′ - flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803-808.
13. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C>A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
14. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5: 60-69.
15. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: Sequence, gene structure, comparison with mouse and rat orthologous gene, and differences in liver mRNA expression. Mol Endocrinol 1989; 3: 1399-1408.
16. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ et al. Five novel natural allelic variants - 951 A4C, 1042 G4A (D348N), 1156A4T (I386F), 1217 G4A (C406Y) and 1291 C4T (C4341Y) - of the mutation in a French Caucasian population. Hum Mutat 2001; 17: 355-360.
17. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142-1145.
18. Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol 2002; 54: 299-312.
19. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28: 99-112.
20. Coon H, Jensen S, Holik J, Hoff M, Myles-Worsley M, Reimherr F et al. Genomic scan for genes predisposing to schizophrenia. Am J Med Genet 1994; 54: 59-71.
21. Freedman A, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94: 587-592.
22. Kaufman CA, Suarez B, Malaspina D, Pepel J, Svarakic D, Meyer J et al. NIMH genetics initiative millenium schizophrenia consortium: linkage analysis of African American pedigrees. Am J Med Genet 1998; 88: 29-33.
23. Stober G, Saar K, Ruschendorf F, Meyer J, Nurnberg G, Jatzke S et al. Splitting schizophrenia: Periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet 2000; 67: 1201-1207.
24. Morse DC, Steim AP, Thomas PE, Lowndess HE. Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain. Toxicol Appl Pharmacol 1998; 152: 232-239.
25. Guy W ed. Early Clinical Drug Evaluation Unit b Assessment Manual. US Department of Health and Human Services, National Institute of Mental Health (NIMH): Rockville, MD, 1976.
26. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59 97-105.
27. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68 978-989.
28. Stephens M, Donnelly P. Comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.